• Clinical Evidence Supporting Respiratory Outcomes

    AeroEclipse logoLet Breathing Take Control
     
    The AEROECLIPSE® II BAN® Nebulizer creates aerosol only in response to the patient’s inspiratory flow.

    Aerochamber logoNot All Chambers Are Equal
     
    Some “antistatic” valved holding chambers are only poorly antistatic and are noninterchangeable, which means that switching between them should be discouraged.1

    Aerobika logoImproves Patient Outcomes
     
    Recent publications support use of the AEROBIKA® Oscillating Positive Expiratory Pressure device to help reduce readmissions or improve aerosol deposition when used alongside standard of care.2

    Science Backed, Outcome Driven

     

    Recent Poster Presentations

    25 Cost of Wasted MDI Meds in 4 Mask Chambers ATS

    The High Price of Inhaler Waste – ATS 2025

    The recent transition of fluticasone propionate (FP) to an authorized generic has significant cost implications for patients who rely on this inhaler for disease management. This poster evaluated four chambers available in the US to assess drug delivery and the cost impacts of these differences. By enhancing the amount of medication that reaches the lungs with each puff, patients may experience better disease control and require less reliever medication. Download the PDF.

     

    Optimizing Delivery of AirSupra in 2 Chamber Varieties – ATS 2025

    Our Valved Holding Chambers can be effective in reducing oropharyngeal deposition, facilitating effective lung delivery and lowering the risk of systemic side effects. This poster highlights in vitro lab data supporting how our Valved Holding Chambers can deliver the intended dose while also reducing deposition in the mouth and throat compared to using the inhaler alone. The novel design of a chamber and carrying case in one, may also help improve therapy compliance by keeping the MDI protected while on-the-go. Download the PDF.

    25 MP VHC and AeroChamber2Go with AirSupra ATS

     

     

    Aeroeclipse in use

    AEROECLIPSE® II BAN® Nebulizer

    Let Breathing Take Control

    The AEROECLIPSE® II BAN® Nebulizer is a leading-edge device designed for efficient medication delivery. It produces aerosol only on inhalation, reducing medication waste and the aerosol particulate that ends up in the room by 3-4 times than that of a continuously run jet nebulizer.3,4 This helps minimize exposure to environmental loss for front line healthcare professionals.

    Illustration of drug deposition in lungs

    Clinical Evidence

    Not all jet nebulizers are created equal. For dose assurance and a safe environment for your frontline staff, choose AEROECLIPSE® II BAN® Nebulizer.

    The study reports use can significantly reduce hospital admissions and emergency department bed hours for asthma and COPD exacerbations, leading to substantial cost savings and improved operational efficiency. Despite a modest increase in per-unit cost, the investment pays for itself many times over, driven by shorter patient stays and a significant reduction in avoidable admissions. See the full details and calculate the value it could bring your ED here.

    Learn more.

    This study reinforces how nebulizer design affects therapeutic dose to the patient and how the AEROECLIPSE® II BAN® Nebulizer can create safer environments by decreasing environmental loss. Learn more.

    Implementation of the AEROECLIPSE® II BAN® Nebulizer in a hospital Emergency Department resulted in an 88% reduction in the cost of sick days by reducing the number of sick days by 60%. Learn more.

    This bench study evaluated the environmental loss of 10 commonly used small volume nebulizer using 4 simulated adult breathing patterns. As exhalation time increased, environmental loss increased for all nebulizers except the AEROECLIPSE® II BAN® Nebulizer. These findings could help develop policies and best practices for the risk mitigation of fugitive emissions from nebulizing systems. Learn more.

    This Study Summary is designed to identify how the AEROECLIPSE® II BAN™ Nebulizer has performed in both in vitro and in vivo studies with various formulations and versus other nebulizers. Learn more.

     

     

    AEROCHAMBER PLUS® FLOW-VU® AVHC

    For respiratory patients, getting the most from life means getting the most from their inhaler medication.

    AEROCHAMBER PLUS® brand of chambers delivers the intended dose established by the pharmaceutical company.⁶ Use of other chambers may lead to medication waste, less than optimal doses, and varying therapeutic responses.

    Clinical Evidence

    This study uses Functional Respiratory Imaging (FRI) deposition profiles to highlight the significant negative impact on lung deposition of even a relatively short 0.5 second delay between actuation and inhalation when an MDI is used alone. Use of an AEROCHAMBER PLUS® FLOW-VU® aVHC, even with a 2 second delay, demonstrated greater central lung delivery than the MDI alone with perfect coordination reinforcing the importance of chamber use for all people using MDIs. Learn more.

    Only AEROCHAMBER PLUS® FLOW-VU® chambers were equivalent to the reference device data listed in virtually all innovator inhalers currently approved in the US and European markets. Differences in chamber design, materials and function mean that chambers should not be automatically considered interchangeable. Learn more.

    The author found that it was unequivocal that differences exist between different chambers which in a number of cases are sufficiently large that meaningful and overt clinical differences would be anticipated as a result. Learn more.

    Peripheral lung deposition was appreciably higher using the AEROCHAMBER PLUS® FLOW-VU® aVHC versus two competitive chambers. These results highlight that Valved Holding Chambers should not be considered interchangeable. Learn more.

    Inspiratory flow rate is known to influence drug delivery. This study assessed an MDI + chamber and two DPI systems at optimal and sub-optimal flow rates to determine the impact of drug delivery (modelled using Functional Respiratory Imaging). Learn more.

    The recent transition of fluticasone propionate (FP) to an authorized generic could have aerosol delivery changes that may affect dosing to the lungs and have significant cost implications for patients who rely on this inhaler for disease management. This poster evaluated the different drug delivery profiles of four chambers and assessed the cost impacts of these differences. By enhancing the potential amount of medication that reaches the lungs with each puff, patients may experience better disease control and require less reliever medication. Learn more

    This Study Summary is designed to identify how the AEROCHAMBER PLUS® FLOW-VU® Chambers has performed in both in vitro and in vivo studies with various formulations and versus other chambers. Learn more.

    Aerochamber in use

     

     

    Aerobika device in use
    Lung scan image

    AEROBIKA® OPEP Device

    Oscillating Positive Expiratory Pressure or OPEP therapy helps stent open and clear blocked airways. On exhalation the device creates a unique oscillation and pressure dynamic to address the structural and functional challenges in the airways. The combination of oscillations and pressure opens the airways and aids in moving mucus into the central airways, where it can be coughed out. The device is drug-free so there are no side effects or drug interactions and it is easy-to-use, so patients are able to transition home with the device.

    Clinical Evidence

    There is growing pressure to improve care and reduce hospital admissions. The AEROBIKA® OPEP device offers both clinical benefits and cost savings by significantly reducing COPD readmissions by 28% in the critical 30 days post-exacerbation.

    The AEROBIKA® OPEP device is a cost-effective solution for preventing and treating post-operative pulmonary complications. This real world study reports a 39% reduction in all-cause re-hospitalizations, shorter hospital stays, and 80% lower post-discharge costs compared to standard care. Learn more.

    This study evaluated delivery of hypertonic saline using an AEROECLIPSE® XL R BAN® Nebulizer attached to the AEROBIKA® OPEP device. Use of combination therapy in which neither treatment is diminished, will reduce the burden of care with the benefit of treatment time savings for mucus management in bronchiectasis patients. Learn more.

    This real-world study looked at the difference in post-surgical patient outcomes between those given an AEROBIKA® OPEP device versus Incentive Spirometry (IS). The mean number of PPCs per patient with access to devices on day 1 was .57 for OPEP and .77 for IS, highlighting the fact that current US hospital practice favors introducing IS earlier than OPEP for post-operative care. Learn more.

    This Study Summary is designed to identify how the AEROBIKA® OPEP Device has performed in in both in vitro and in vivo studies and versus other PEP and OPEP devices. Learn more.

     

     

    Words or phrases accompanied by ™ and ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation.

    References

    1. Hagedoorn P, et al. J Aller Clin Immunol 2020;8(3): 1124-1125e4.
    2. Burudpakdee C, et al. Pulmonary Therapy 2017;3(1):163-171; Burudpakdee C, et al. Pulmonary Therapy 2018;4(1):87-101; and Leemans G, et al. COPD 2020;15: 1261–1268.
    3. Rau, JL, et al. Performance Comparison of Nebulizer Designs: Constant-Output, Breath-Enhanced, and Dosimetric. Resp Care 2004;(49):174-179 and TMI Aerosol Lab, data on file (600cc, 10BPM, 1:2, Albuterol Sulfate Inhalation Solution 833µg/mL).
    4. Nagel M, et al. Am J Respir Crit Care Med 2021;203:A4672.
    5. Nagel M, Suggett J, Mitchell JP. RDD 2021;1:287-292.